Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Ramon Tiu is an Assistant Professor of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is associate staff in the Department of Translational Hematology and Oncology Research and Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic. He completed his medical school training at the University of Santo Tomas Faculty of Medicine and Surgery in the Philippines and subsequently pursued internal medicine training at Cleveland Clinic from 2003-2006. He pursued further research training in experimental hematology as a bone marrow failure research fellow at Cleveland Clinic under the tutelage of Dr. Jaroslaw P. Maciejewski, which he continued throughout his fellowship training in hematology and oncology at the same institution. He is well published in the area of single nucleotide polymorphism arrays, especially in their clinical application in myeloid malignancies like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He is a young investigator awardee from the MDS Foundation and the Aplastic Anemia and MDS International Foundation and a prior recipient of a T32 research award from Case Western Reserve University. He is involved in both clinical and translational research, focusing mainly on the field of myeloproliferative neoplasms and bone marrow failure syndromes. His laboratory research team recently identified a gene called SF3B1 to be frequently mutated in cases of MDS with ring sideroblasts, specifically refractory anemia with ring sideroblasts (RARS) and RARS associated with marked thrombocytosis (RARS-T). SF3B1 is a gene involved in an important physiologic post-transcriptional process called splicing. This is an unprecedented finding, as this is the first time that the spliceosome machinery has been implicated as a possible cause in blood cancers, particularly in MDS. Recently, his research team showed the first experimental evidence linking SF3B1 dysfunction and the formation of ring sideroblast in MDS. He is also very active in conducting clinical trials in bone marrow failure syndromes and myeloproliferative neoplasms (MPNs) and an active clinician seeing patients with MDS, MDS/MPN overlap syndromes, MPNs and rare bone marrow failure conditions like Aplastic Anemia, PNH and LGL leukemia. He is board certified in Internal Medicine, Hematology and Oncology.
Myeloproliferative disorders/neoplasms myelodysplastic syndromes, large granular lymphocyte leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, cancer, pancytopenia, leukemia, cytopenia, chronic myelomonocytic leukemia (CMML)
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Tiu's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.